Altre lingue Eisai Co., Ltd.

Azioni

4523

JP3160400002

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 17/05/2024			Variaz. 5gg	Var. 1 gen.
6.779 ^JPY	-1,27%		-0,21%	-3,87%

16/05	L'utile attribuibile di Eisai scende del 23,5% nell'anno fiscale 2024	MT
15/05	BioArctic, Eisai lanciano la domanda di autorizzazione alla FDA statunitense per il dosaggio di mantenimento di Leqembi	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Interim Report for the period January - March 2024	17/05
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	16/05
Eisai's Attributable Profit Falls 23.5% in Fiscal 2024	16/05
BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing	15/05
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	15/05
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA	15/05
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)	15/05
Eisai Co., Ltd. announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.	15/05
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing	15/05
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	15/05
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA	15/05
Eisai Co., Ltd. authorizes a Buyback Plan.	15/05
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures	13/05
Panel de la FDA discutirá el 10 de junio un fármaco de Eli Lilly contra el Alzheimer	07/05
People with two copies of a risk gene have genetic form of Alzheimer's, scientists say	06/05
BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024	25/04
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024	24/04
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	24/04
Alzheimer's drug adoption in US slowed by doctors' skepticism	23/04
BioArctic and Eisai sign research evaluation agreement regarding BAN2802	20/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Eisai Co., Ltd.

Azioni

4523

JP3160400002

Altre lingue

Filtri